Compare SEAT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | PCRX |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | 829 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 949.9M |
| IPO Year | 2021 | 2010 |
| Metric | SEAT | PCRX |
|---|---|---|
| Price | $7.02 | $24.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $18.06 | ★ $30.25 |
| AVG Volume (30 Days) | 57.5K | ★ 643.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | $4.60 | $8.54 |
| P/E Ratio | ★ N/A | $125.42 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $5.06 | $18.80 |
| 52 Week High | $18.73 | $27.66 |
| Indicator | SEAT | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 47.36 |
| Support Level | $5.80 | $21.71 |
| Resistance Level | $7.85 | $27.08 |
| Average True Range (ATR) | 0.62 | 0.97 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 8.64 | 32.34 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.